14 February 2019 - Deborah Wilkes
Archived
Moberg Pharma is divesting its OTC business to two private-equity firms in a cash deal worth SEK1.43 billion (USD155 million). The Swedish company plans to focus on developing and commercialising MOB-015, its novel topical terbinafine formulation for treating nail fungus.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.